Basit öğe kaydını göster

dc.contributor.authorKuskonmaz, Baris
dc.contributor.authorYalcin, Songul
dc.contributor.authorKucukbayrak, Ozlem
dc.contributor.authorCetin, Nevin
dc.contributor.authorCetin, Mualla
dc.contributor.authorTezcan, İlhan
dc.contributor.authorUckan, Duygu
dc.date.accessioned2020-10-21T12:37:06Z
dc.date.available2020-10-21T12:37:06Z
dc.date.issued2008
dc.identifier.issn1399-3046
dc.identifier.urihttp://hdl.handle.net/11655/22998
dc.description.abstractHSCT associated morbidity and mortality is usually attributed to high-dose chemotherapy/radiotherapy regimens used for conditioning. Glutamine (Gln), a conditionally essential amino acid during severe catabolic states, has been shown to have favorable effects in patients with malignancies and in those undergoing HSCT. However, controversy exists regarding its routine use. Studies in children investigating gln supplementation are very limited. In the present study, including 21 gln-supplemented and 20 control pediatric patients, gln supplementation was shown to reduce the duration of fever and decrease the incidence of SOS during the HSCT course. In addition, a decrease in drug-related toxicity and a trend toward reduced incidence of severe mucositis were observed.tr_TR
dc.language.isoentr_TR
dc.publisherWileytr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectglutamine supplementation transplantationtr_TR
dc.titleThe Effect of Glutamine Supplementation on Hematopoietic Stem Cell Transplant Outcome in Children: A Case-Control Studytr_TR
dc.typeinfo:eu-repo/semantics/articletr_TR
dc.relation.journalPediatric Transplantationtr_TR
dc.contributor.departmentÇocuk Sağlığı ve Hastalıklarıtr_TR
dc.identifier.volume12tr_TR
dc.identifier.issue1tr_TR
dc.description.indexWoStr_TR
dc.fundingYoktr_TR


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster